Livre Blanc
In the Eye of the Storm: PD-(L)1 Inhibitors Weathering Turbulence
May 09, 2022
Download

Harnessing the power of the body’s immune system for the fight against cancer has been one of the most remarkable success stories of the past decade. PD-(L)1 checkpoint inhibitors have transformed the cancer treatment landscape and emerged as one of the most dynamic market segments, growing at 5-year CAGR of 45%, or three times the rate of oncology overall. However, the checkpoint inhibitor market is facing strong headwinds as competition intensifies and development activity surges.

In our latest white paper, we review the competitive dynamics and emerging innovation landscape for PD-(L)1 inhibitors, examine the challenges the market is facing and explore future opportunities and considerations for capturing these.

Contact Us